1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => OpenAccess
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
RT Journal Article
SR Electronic
T1 Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists
JF American Journal of Neuroradiology
JO Am. J. Neuroradiol.
FD American Society of Neuroradiology
SP 738
OP 750
DO 10.3174/ajnr.A6477
VO 41
IS 5
A1 Dodson, C.
A1 Richards, T.J.
A1 Smith, D.A.
A1 Ramaiya, N.H.
YR 2020
UL http://www.ajnr.org/content/41/5/738.abstract
AB SUMMARY: Treatment options for patients who develop brain metastases secondary to non-small-cell lung cancer have rapidly expanded in recent years. As a key adjunct to surgical and radiation therapy options, systemic therapies are now a critical component of the oncologic management of metastatic CNS disease in many patients with non-small-cell lung cancer. The aim of this review article was to provide a guide for radiologists, outlining the role of systemic therapies in metastatic non-small-cell lung cancer, with a focus on tyrosine kinase inhibitors. The critical role of the blood-brain barrier in the development of systemic therapies will be described. The final sections of this review will provide an overview of current imaging-based guidelines for therapy response. The utility of the Response Assessment in Neuro-Oncology criteria will be discussed, with a focus on how to use the response criteria in the assessment of patients treated with systemic and traditional therapies.ALKanaplastic lymphoma kinaseCTLA-4cytotoxic T-lymphocyte-associated protein 4EGFRepidermal growth factor receptorEML4echinoderm microtubule-associated protein-like 4ICIimmune checkpoint inhibitorNSCLCnon-small-cell lung cancerPD-1programmed cell death protein 1PFSprogression-free survivalPRESposterior reversible encephalopathy syndromeQALYquality-adjusted life yearsRANOResponse Assessment in Neuro-OncologyRECISTResponse Evaluation Criteria in Solid TumorsROS1C-ras oncogene 1SRSstereotactic radiosurgeryTKItyrosine kinase inhibitorWBRTwhole-brain radiation therapy